정밀 절단 폐 슬라이스를 활용하여 기도 및 폐 동맥 평활근의 수축 조절 연구

Executive Industry Relevance

Precision-cut lung slices (PCLS) enable ex vivo interrogation of airway and intrapulmonary arterial smooth muscle contractility in a near-native tissue context, supporting mechanistic de-risking in early respiratory drug discovery. This platform preserves in vivo cellular phenotypes and microenvironmental interactions, providing predictive confidence for target validation and functional screening. PCLS models are strategically positioned to bridge discovery biology and translational research in pulmonary disease portfolios.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct assessment of smooth muscle contractile regulation in intact pulmonary tissue.
• Supports mechanistic studies of Ca²⁺-mediated signaling pathways relevant to disease pathogenesis.
• Facilitates functional target validation by preserving native cell-cell and cell-matrix interactions.
• Provides a platform for hypothesis-driven interrogation of airway and vascular responses.

Screening & Assay Development

• Delivers reproducible, quantitative readouts of airway and vascular contraction for compound evaluation.
• Supports standardization of bioassays for bronchodilator and vasodilator screening.
• Enables scalability for comparative studies across multiple conditions or genetic models.
• Prepares validated biological systems for downstream pharmacological testing.

Translational & Preclinical Research

• Aligns with disease-relevant mechanisms in models of asthma and pulmonary hypertension.
• Maintains translational continuity by modeling deregulated smooth muscle contractility ex vivo.
• Supports risk-adjusted advancement decisions by providing functional evidence of target engagement.
• Facilitates biomarker discovery through quantitative imaging of contractile and signaling responses.

Pipeline & Workflow Integration

PCLS technology integrates from early discovery through lead identification and preclinical validation in respiratory drug development workflows.

• Discovery Biology: Enables hypothesis testing of contractile regulation and pathway involvement in pulmonary tissue.
• Screening: Provides assay-ready, reproducible models for evaluating pharmacological modulation of smooth muscle.
• Analytics: Delivers quantitative measurements of luminal area reduction and Ca²⁺ signaling dynamics.
• Translational Research: Bridges ex vivo findings to in vivo disease models for mechanistic continuity.
• Enterprise Reuse: Offers a reusable platform adaptable to diverse respiratory disease research needs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in target validation and mechanistic de-risking.
• Operational Value: Enhances standardization, reproducibility, and scalability of functional assays.
• Strategic Value: Improves go/no-go decision-making and reduces late-stage biological risk.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of respiratory programs.

Implementation Considerations

• Requires expertise in pulmonary tissue handling and live imaging techniques.
• Demands access to vibratome slicing, confocal microscopy, and quantitative imaging infrastructure.
• Necessitates cross-team standardization of slice preparation and assay protocols.
• Adaptation may be needed for different species or disease models.
• Practical limitations include slice viability duration and potential variability in tissue quality.

Biopharma FAQs